FDP cyclic adenosine monophosphate compound drink composition with myocardial protection effect

Abstract

The invention relates to the technical field of nutritional health-care drinks, in particular to an FDP cyclic adenosine monophosphate compound drink composition with a myocardial protection effect. The formula comprises the following raw materials: 8 g of water, 2 g of a red date extracting solution, 0.15 g of 1, 6-fructose diphosphate trisodium salt, 0.1 g of deer myocardial peptide powder, 0.1 g of anhydrous citric acid, 0.004 g of potassium sorbate, 0.00003 g of vitamin B1, 0.00003 g of vitamin B2 and 0.00003 g of vitamin B6. The preparation method comprises the following steps: molecular docking; performing ultrasonic synergism; carrying out steady-state treatment; and mixing. The invention provides the FDP cyclic adenosine monophosphate compound drink composition with the myocardial protection effect, and the efficacy improvement and clinical application value of a compound myocardial protection product are improved.

Description

Technical Field

[0001] The present invention relates to the technical field of nutritional and health care beverages, and particularly to an FDP cyclic adenosine monophosphate composite beverage composition with myocardial protection effect. Background Art

[0002] Cardiovascular health is an important foundation for maintaining human body functions, and myocardial protection, as a key link in the prevention and intervention of cardiovascular diseases, has received extensive attention in recent years. With the changes in lifestyle and the aggravation of population aging, the incidence of myocardial injury and related diseases has been rising continuously. Developing safe and effective myocardial protection products has important clinical significance. In the prior art, improving myocardial metabolism and enhancing the anoxia tolerance of cells through nutritional supplementation or active ingredient intervention has become the main research direction. Among them, fructose diphosphate substances and bioactive peptides have attracted much attention due to their unique roles in energy metabolism regulation.

[0003] Currently, the development of myocardial protection products generally faces the following problems: First, the action targets of single active ingredients are limited, and it is difficult to comprehensively cover multiple mechanisms of myocardial cell protection, resulting in limited overall effects; second, intermolecular interactions are likely to occur during the compounding of complex components, and conventional mixing processes cannot achieve effective binding at the molecular level; third, heat-sensitive ingredients are easily affected by factors such as temperature and oxidation during processing, resulting in a decrease in bioavailability. In addition, traditional preparation methods are difficult to accurately simulate the myocardial cell microenvironment, making it difficult for active ingredients to form a spatial conformation that matches the physiological state, directly affecting their binding efficiency with targets. Summary of the Invention

[0004] The present invention provides an FDP cyclic adenosine monophosphate composite beverage composition with myocardial protection effect, improving the efficacy and clinical application value of composite myocardial protection products.

[0005] The technical solution adopted by the present invention is as follows: An FDP cyclic adenosine monophosphate composite beverage composition with myocardial protection effect, the raw material composition includes: water accounts for 8 grams, red date extract accounts for 2 grams, trisodium 1,6-diphosphate fructose accounts for 0.15 grams, deer myocardial peptide powder accounts for 0.1 gram, anhydrous citric acid accounts for 0.1 gram, potassium sorbate accounts for 0.004 gram, vitamin B1 accounts for 0.00003 gram, vitamin B2 accounts for 0.00003 gram, vitamin B6 accounts for 0.00003 gram; its preparation method includes:

[0006] Step 1, molecular docking: Molecular docking is carried out on deer myocardial peptide powder and trisodium 1,6-diphosphate fructose in a buffer solution (pH 7.2 - 7.6, containing 0.1 mM Ca 2+ ) simulating the myocardial cell membrane environment, the docking temperature is 25 - 30 °C, and the time is 1 - 2 hours;

[0007] Step 2, ultrasonic enhancement: The docking product is subjected to three-stage ultrasonic cell disruption treatment;

[0008] Step 3, stabilization treatment: The disrupted product is allowed to stand and ripen at 4°C for 12 hours under nitrogen protection;

[0009] Step 4, mixing treatment: After ripening is completed, 20% red date extract, potassium sorbate, vitamin B1, vitamin B2, and vitamin B6 are added to the product to allow the components to fully blend.

[0010] As a further improvement of the present invention, 0.06 - 0.08 g of astragalus extract, 0.003 - 0.004 g of tanshinone, and 0.001 - 0.002 g of notoginsenoside R1 are added, and a liposome-encapsulated complex is prepared by the reverse evaporation method. The liposome has a particle size of 80 - 120 nm, an encapsulation efficiency of ≥93%, and the surface is modified with polyethylene glycol (PEG2000).

[0011] As a further improvement of the present invention, the molecular docking process uses microwave-assisted technology with a microwave power of 300 - 500 W, a frequency of 2.45 GHz, an irradiation time of 30 - 60 seconds, and a microwave pulse interval of 5 seconds.

[0012] As a further improvement of the present invention, the parameters of the three-stage ultrasonic treatment are as follows:

[0013] First-stage treatment: Power 500 W, frequency 33 kHz, pulse mode (on for 2 s / off for 1 s), time 10 minutes;

[0014] Second-stage treatment: Power 600 W, frequency 40 kHz, continuous mode, time 8 minutes;

[0015] Third-stage treatment: Power 400 W, frequency 28 kHz, intermittent mode (on for 1 s / off for 0.5 s), time 5 minutes.

[0016] As a further improvement of the present invention, the ultrasonic treatment is carried out throughout in a high-pressure carbon dioxide environment with a pressure of 8 - 12 MPa, a CO2 flow rate of 2 - 4 L / min, and after treatment, it is depressurized to atmospheric pressure at a rate of 0.5 MPa / min.

[0017] As a further improvement of the present invention, 0.02 - 0.03 g of epigallocatechin gallate (EGCG) is added as an antioxidant synergist during the stabilization treatment process, and nano-dispersion treatment is carried out by the microfluidic technology before ripening with a jet pressure of 150 - 180 MPa and circulating 3 times.

[0018] As a further improvement of the present invention, the mixing treatment is carried out with stirring and mixing evenly at a temperature of 30 - 35°C, a stirring speed of 200 - 300 revolutions per minute, and continuous stirring for 30 - 40 minutes.

[0019] Advantages of the present invention: By optimizing the spatial conformation of active ingredients through molecular docking and achieving efficient cell disruption and stability regulation through the synergistic effect of three-stage ultrasound in a high-pressure carbon dioxide environment, combined with a liposome-targeted delivery system and antioxidant nano-dispersion technology, a multi-component synergistic protection network is constructed at the molecular-cell two-dimensional level, significantly improving the bioavailability and targeted binding efficiency of FDP and myocardial peptides. At the same time, the activity of thermosensitive components is effectively maintained through the whole-process inert environment and precise temperature control process, enabling the compound drink to produce a significant synergistic effect in enhancing myocardial cell energy metabolism, inhibiting oxidative damage, and improving microcirculation. Specific embodiments

[0020] In order to make the technical problems, technical solutions, and beneficial effects to be solved by the present application clearer, the following further elaborates on the present application in conjunction with embodiments. It should be understood that the embodiments described herein are only used to explain the present application and are not used to limit the present application.

[0021] The present invention provides an FDP cyclic adenosine monophosphate compound drink composition with myocardial protection effects. The raw material composition includes: 8 grams of water, 2 grams of red date extract, 0.15 grams of fructose-1,6-diphosphate trisodium salt, 0.1 gram of deer myocardial peptide powder, 0.1 gram of anhydrous citric acid, 0.004 gram of potassium sorbate, 0.00003 gram of vitamin B1, 0.00003 gram of vitamin B2, and 0.00003 gram of vitamin B6. Its preparation method includes:

[0022] Step 1, molecular docking: Perform molecular docking on deer myocardial peptide powder and fructose-1,6-diphosphate trisodium salt in a buffer solution (pH 7.2 - 7.6, containing 0.1 mM Ca 2+ ) in an environment simulating the myocardial cell membrane, with a docking temperature of 25 - 30 °C and a time of 1 - 2 hours;

[0023] Step 2, ultrasonic enhancement: Subject the docking product to three-stage ultrasonic cell disruption treatment;

[0024] Step 3, stabilization treatment: Let the disrupted product stand and ripen at 4 °C for 12 hours under nitrogen protection;

[0025] Step 4, mixing treatment: After the ripening is completed, add 20% red date extract, potassium sorbate, vitamin B1, vitamin B2, and vitamin B6 to the product to make each component fully blend.

[0026] The present invention adds 0.06 - 0.08 g of astragalus extract, 0.003 - 0.004 g of tanshinone, and 0.001 - 0.002 g of notoginsenoside R1, and uses the reverse evaporation method to prepare a liposome-encapsulated complex. The liposome has a particle size of 80 - 120 nm, an encapsulation efficiency of ≥93%, and the surface is modified with polyethylene glycol (PEG2000).

[0027] In the molecular docking process of the present invention, microwave-assisted technology is adopted, with a microwave power of 300 - 500 W, a frequency of 2.45 GHz, an irradiation time of 30 - 60 seconds, and a microwave pulse interval of 5 seconds.

[0028] The parameters of the three-stage ultrasonic treatment in the present invention are as follows:

[0029] First-stage treatment: power 500 W, frequency 33 kHz, pulse mode (on for 2 s / off for 1 s), time 10 minutes;

[0030] Second-stage treatment: power 600 W, frequency 40 kHz, continuous mode, time 8 minutes;

[0031] Third-stage treatment: power 400 W, frequency 28 kHz, intermittent mode (on for 1 s / off for 0.5 s), time 5 minutes.

[0032] The ultrasonic treatment of the present invention is carried out throughout in a high-pressure carbon dioxide environment, with a pressure of 8 - 12 MPa, a CO2 flow rate of 2 - 4 L / min, and after treatment, it is depressurized to atmospheric pressure at a rate of 0.5 MPa / min.

[0033] During the stabilization treatment of the present invention, 0.02 - 0.03 g of epigallocatechin gallate (EGCG) is added as an antioxidant synergist, and nano-dispersion treatment is carried out by microfluidics technology before ripening, with a jet pressure of 150 - 180 MPa and 3 cycles.

[0034] The whole process of the mixing treatment of the present invention is stirred and mixed evenly at a temperature of 30 - 35 °C, with a stirring speed of 200 - 300 revolutions per minute, and continuous stirring for 30 - 40 minutes.

[0035] Example (parts by weight × 100):

[0036] Weigh 15 g of fructose-1,6-diphosphate trisodium salt and 10 g of deer myocardial peptide powder, and add phosphate buffer (pH 7.4, containing 0.1 mM Ca 2+) It was placed in a microwave reactor for molecular docking. The microwave power was set at 400 W, the frequency was 2.45 GHz, and it was processed in a pulsed mode (irradiation for 30 s / interval for 5 s) for 3 cycles. The total irradiation time was 90 s, and the reaction temperature was controlled at 28 °C ± 2 °C for 1.5 h. Subsequently, the mixture was transferred to a three-stage ultrasonic cell disruptor and successively carried out under a high-pressure carbon dioxide environment (pressure 10 MPa, CO2 flow rate 3 L / min):

[0037] Primary treatment: power 500 W, frequency 33 kHz, pulsed mode (on for 2 s / off for 1 s), treated for 10 minutes;

[0038] Secondary treatment: power 600 W, frequency 40 kHz, continuous mode treated for 8 minutes;

[0039] Tertiary treatment: power 400 W, frequency 28 kHz, intermittent mode (on for 1 s / off for 0.5 s) treated for 5 minutes.

[0040] After treatment, it was depressurized to atmospheric pressure at a rate of 0.5 MPa / min to obtain a nanoscale dispersion with a particle size distribution of 50 - 150 nm.

[0041] 2.5 g of EGCG was added to the crushed product. After being treated by a microfluidic nanodispersion system (jet pressure 165 MPa, circulated 3 times), it was transferred to a sealed reaction tank. After purging the air with nitrogen, it was left to age at 4 °C for 12 h. After aging, a pretreated liposome encapsulation complex (containing 7 g of astragalus extract, 0.35 g of tanshinone, 0.15 g of notoginsenoside R1, PEG2000-modified liposomes prepared by the reverse evaporation method, particle size 102 ± 15 nm, encapsulation efficiency 94.3%) was added, and then 200 g of 20% red date extract, 10 g of anhydrous citric acid, 0.4 g of potassium sorbate, and vitamin B group (B1 0.003 g, B2 0.003 g, B6 0.003 g) were added successively.

[0042] Finally, 800 g of water was added to a constant-temperature stirring reactor at 32 °C and continuously stirred at 250 rpm for 35 minutes. Sampling and testing showed that:

[0043] (1) The retention rate of active ingredients ≥ 98% (detected by HPLC, compared with the untreated raw material);

[0044] (2) The release rate of the liposome encapsulation complex in simulated gastric juice within 2 h < 10%, and the cumulative release rate in intestinal juice reached 92% within 4 h;

[0045] (3) The DPPH free radical scavenging rate was increased by 41% compared with the conventional process (EGCG synergistic effect);

[0046] (4) Transmission electron microscopy showed that the FDP-cardiotide complex had a uniform spherical structure with a particle size of 80 - 120 nm and a Zeta potential of -25.3 mV.

[0047] As can be seen from the above examples, the FDP-cyclic adenosine monophosphate composite drink composition prepared by the present invention performs excellently in terms of retaining active ingredients, targeted release, antioxidant capacity and microstructure stability, fully verifying the effectiveness of the synergistic effect of each technical link. By strictly controlling various parameters in the preparation process, efficient combination and stable existence among multiple components are achieved, providing an innovative and feasible technical path for the development of myocardial protection nutritional health drinks.

[0048] In summary, a FDP-cyclic adenosine monophosphate composite drink composition with myocardial protection effect of the present invention successfully overcomes many problems faced by existing myocardial protection products through a unique raw material formula and advanced preparation process. It not only effectively improves the efficacy of composite myocardial protection products, but also lays a solid foundation for improving their clinical application value. The innovative process of the invention, from molecular docking, ultrasonic enhancement to steady-state treatment, and subsequent mixing treatment and other series of steps, accurately and efficiently ensures the activity and synergistic effect of each component, which is of great significance for promoting the development of the field of cardiovascular disease prevention and intervention, and is expected to provide better and more effective nutritional health options for vast numbers of cardiovascular disease patients and people concerned about myocardial health.

[0049] The above examples are only used to illustrate the technical solutions of the present invention, rather than to limit it; although the present invention has been described in detail with reference to the foregoing examples, those of ordinary skill in the art should understand that: they can still modify the technical solutions recorded in the foregoing examples, or perform equivalent replacements on some of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A FDP cyclic adenosine monophosphate composite drink composition with myocardial protection effect, characterized in that, The raw material composition includes: 8 g of water, 2 g of red date extract, 0.15 g of fructose 1,6-diphosphate trisodium salt, 0.1 g of deer myocardial peptide powder, 0.1 g of anhydrous citric acid, 0.004 g of potassium sorbate, 0.00003 g of vitamin B1, 0.00003 g of vitamin B2, and 0.00003 g of vitamin B6; its preparation method includes: Step 1, molecular docking: Molecular docking is carried out on deer myocardial peptide powder and fructose 1,6-diphosphate trisodium salt in a buffer solution (pH 7.2 - 7.6, containing 0.1 mM Ca 2+ ) under the condition of simulating the myocardial cell membrane environment, with the docking temperature of 25 - 30 °C and the time of 1 - 2 hours; Step 2, ultrasonic enhancement: The docking product is processed by three-stage ultrasonic cell disruption. Step 3, stabilization treatment: The disrupted product is allowed to stand and ripen at 4°C for 12 hours under nitrogen protection. Step 4, mixing treatment: After the ripening is completed, 20% red date extract, potassium sorbate, vitamin B1, vitamin B2, and vitamin B6 are added to the product to make the components fully blend.

2. The FDP-cyclic adenosine monophosphate composite drink composition with myocardial protection effect according to claim 1, wherein, Add 0.06 - 0.08 g of astragalus extract, 0.003 - 0.004 g of tanshinone, and 0.001 - 0.002 g of notoginsenoside R1, and prepare a liposome-encapsulated complex by the reverse evaporation method. The liposome has a particle size of 80 - 120 nm and an encapsulation efficiency of ≥93%, and the surface is modified with polyethylene glycol (PEG2000).

3. The FDP-cyclic adenosine monophosphate composite drink composition with a myocardial protection effect according to claim 1, wherein The molecular docking process uses microwave-assisted technology with a microwave power of 300 - 500 W, a frequency of 2.45 GHz, an irradiation time of 30 - 60 seconds, and a microwave pulse interval of 5 seconds.

4. A FDP cyclic adenosine monophosphate composite drink composition with a myocardial protection effect according to claim 1, characterized in that, The parameters of the three-stage ultrasonic treatment are as follows: First-stage treatment: Power 500 W, frequency 33 kHz, pulse mode (on for 2 s / off for 1 s), time 10 minutes. Second-stage treatment: Power 600 W, frequency 40 kHz, continuous mode, time 8 minutes. Third-stage treatment: Power 400 W, frequency 28 kHz, intermittent mode (on for 1 s / off for 0.5 s), time 5 minutes.

5. The FDP-cyclic adenosine monophosphate composite drink composition with myocardial protection effect according to claim 4, characterized in that, The ultrasonic treatment is carried out throughout in a high-pressure carbon dioxide environment with a pressure of 8 - 12 MPa, a CO2 flow rate of 2 - 4 L / min, and after treatment, it is depressurized to atmospheric pressure at a rate of 0.5 MPa / min.

6. The FDP cyclic adenosine monophosphate composite drink composition with myocardial protection effect according to claim 1, wherein During the stabilization treatment process, 0.02 - 0.03 g of epigallocatechin gallate (EGCG) is added as an antioxidant synergist, and nano-dispersion treatment is carried out by microfluidics technology before ripening, with a jet pressure of 150 - 180 MPa and 3 cycles.

7. The FDP-cyclic adenosine monophosphate composite drink composition with myocardial protection according to claim 1, wherein, The mixing treatment is carried out with stirring at a temperature of 30 - 35°C until evenly mixed, with a stirring speed of 200 - 300 revolutions per minute and continuous stirring for 30 - 40 minutes.